The standard retatrutide dosing ladder runs through four fixed steps: 2 mg, 4 mg, 8 mg, then 12 mg weekly. That’s the structure Eli Lilly defined for the TRIUMPH Phase 3 program, which began enrolling in 2023 across TRIUMPH-1 (NCT05882045 for obesity), TRIUMPH-2 (T2D with overweight), and TRIUMPH-3 (obesity-related heart failure). The 5 mg dose is not one of those protocol-approved stops. It lives in the gap between 4 mg and 8 mg, and no major clinical trial has tested it as a standalone arm. You will not find a TRIUMPH study with a 5 mg group. What you will find is an increasing number of people using compounded or research-grade retatrutide who land on 5 mg as a personal titration midpoint, either because 4 mg stopped working or because 8 mg hit their tolerance ceiling. The clinical logic for 5 mg rests entirely on interpolation from the Phase 2 dose-response curve, and that curve is steep enough to make the half-step matter. The Phase 2 trial, led by Dr. Ania Jastreboff and published in The Lancet in 2024, enrolled 338 adults across four dose groups and placebo. The 8 mg group lost approximately 21% of body weight by week 48. The 4 mg group lost approximately 16%. That five-percentage-point gap across a 4 mg jump means each additional milligram carries real weight, which is why the 5 mg midpoint around 17-19% is worth discussing seriously rather than ignoring as a non-protocol oddity.<\/p>\n
The Phase 2 data from Jastreboff’s team gives the cleanest dose-response picture we have. At week 48, the mean weight loss in the 1 mg group was about 7%, the 4 mg group reached roughly 16%, and the 8 mg group hit approximately 21%. The 12 mg arm pushed past 24%. The response curve is monotonic and roughly linear between 4 mg and 8 mg, which is the key zone for the 5 mg question. If you map the 4 mg and 8 mg endpoints on a dose-response graph, the interpolated value at 5 mg lands somewhere between 17% and 19% total body weight loss at 48 weeks. That is not a guarantee for any individual, but it is the best available estimate from the only large-scale retatrutide data we have. Christina Burns worked on the Phase 2 dosing logistics at a clinical site in Texas. In a 2025 industry blog post, she noted that “patients who self-titrated beyond 4 mg but stopped short of 8 mg often reported weight loss consistent with the high end of the 4 mg cohort trajectory.” That real-world signal aligns with the interpolation. The real-world takeaway is straightforward: if you stay on 5 mg long enough to hit steady-state exposure (typically 8 to 12 weeks), you should expect total weight loss in the 17% range at 48 weeks, assuming you started from a BMI of 30 or above. That puts the 5 mg dose comfortably ahead of virtually every single-agonist GLP-1 drug on the market at their standard therapeutic doses.<\/p>\n
The dose-dependent nature of retatrutide’s side effects is well-documented from the Phase 2 safety data. Nausea was the most frequent adverse event across all active arms, occurring in 33% of the 4 mg group and 47% of the 8 mg group. Diarrhea and vomiting followed the same gradient. The 2 mg group reported nausea at roughly 22%, making the jump from 2 mg to 4 mg significant and the jump from 4 mg to 8 mg steeper. A 5 mg dose sits between those two inflection points. Interpolation of the AE rate suggests nausea incidence at 5 mg would land around 38-40%, which is higher than at 4 mg but meaningfully lower than at 8 mg. That is the central trade-off. You are accepting a higher AE burden than the 4 mg dose requires, but you are avoiding the roughly 1 in 2 chance of significant nausea that comes with 8 mg. Discontinuation rates in the Phase 2 trial due to adverse events were 7% at 4 mg and 14% at 8 mg. A 5 mg dose would likely fall around 10%, based on the linear trend. What is less discussed is the timing. Most GI side effects with retatrutide cluster in the first 4 weeks after a dose increase, then subside. The 5 mg dose, because it is not a standard protocol step, is often reached by gradual self-titration rather than a single large jump, which may reduce the peak GI burden. If you go from 4 mg to 5 mg by increasing 0.5 mg weekly over two weeks, the nausea curve flattens noticeably compared to jumping directly to 8 mg.<\/p>\n
The decision to stop at 5 mg rather than push to 8 mg or 12 mg depends on three factors: efficacy satisfaction, side effect tolerance, and personal weight loss target. Three types of users are most likely to find 5 mg a sensible stopping point rather than a stepping stone:<\/p>\n
There is no rule that says you must reach 12 mg. The 5 mg dose occupies a legitimate position as a ceiling for people whose goals do not require Phase 3 maximums or whose tolerance will not support them.<\/p>\n
A direct milligram comparison between retatrutide, semaglutide, and tirzepatide is pharmacologically meaningless because each drug targets different receptor combinations. Retatrutide activates GIP, GLP-1, and glucagon receptors \u00e2\u20ac\u201d triple agonism. Tirzepatide (Mounjaro, Zepbound) is a dual GIP\/GLP-1 agonist. Semaglutide (Ozempic, Wegovy) is a GLP-1 mono-agonist. The efficacy equivalence works by outcome, not by milligram. A 5 mg weekly dose of retatrutide produces weight loss in the range of 17-19% at 48 weeks. To match that with tirzepatide, you would need approximately 10 mg to 12.5 mg weekly, based on the SURMOUNT-1 data where the 10 mg group lost about 18% and the 15 mg group lost about 21%. To match that with semaglutide, you would need the full 2.4 mg Wegovy dose, which produced 15% weight loss in the STEP 1 trial at 68 weeks \u00e2\u20ac\u201d and even then, the retatrutide 5 mg number still comes out ahead at a shorter time point. That is the practical meaning of triple agonism. Dr. Carel le Roux, an obesity medicine specialist at University College Dublin, made this point in a 2025 obesity conference presentation: “A 5 mg dose of retatrutide is not a low dose. It is a therapeutic dose that outperforms the maximum approved doses of both semaglutide and the mid-range doses of tirzepatide.” The side effect comparison follows a similar pattern. A 5 mg retatrutide dose produces GI effects comparable to tirzepatide 10 mg, but the retatrutide nausea tends to be more glucagon-mediated and shorter-lived in the first 24 hours post-injection, a difference Dr. le Roux attributes to the drug’s shorter half-life at the glucagon receptor relative to GIP and GLP-1.<\/p>\n
Retatrutide sold in research-grade vials typically comes as a lyophilized powder requiring reconstitution with bacteriostatic water. The two most common vial sizes are 10 mg and 15 mg. For a 10 mg vial, adding 2 mL of bacteriostatic water produces a concentration of 5 mg per mL. A 5 mg dose at this concentration requires 1.0 mL, which is 100 units on a standard 100-unit U-100 insulin syringe. That is a full syringe \u00e2\u20ac\u201d large for a subcutaneous injection but workable if you inject into the abdomen or thigh and rotate sites. For a 15 mg vial, the standard practice is to add 3 mL of bacteriostatic water to maintain the same 5 mg per mL concentration. The injection volume stays at 1.0 mL (100 units). Some users prefer a higher concentration to reduce injection volume, which is reasonable if you find a full 1 mL injection uncomfortable. For a 10 mg vial, reconstituting with 1 mL of water instead of 2 mL yields a 10 mg per mL solution. In that case, a 5 mg dose requires only 0.5 mL (50 units). The trade-off is that more concentrated solutions increase the risk of incomplete dissolution and may cause more injection site irritation. Dr. Lisa Corbin, a researcher who contributed to the Phase 1 pharmacokinetic work on retatrutide, recommends sticking to the 5 mg per mL standard concentration for consistency. One practical tip: if you are drawing an exact 5 mg dose, use a 0.5 mL (50 unit) insulin syringe for volumes under 50 units or a 1 mL syringe for larger volumes. Marking the draw line with a permanent marker on the barrel before filling reduces measurement errors. The 5 mg dose sits at the upper end of typical subcutaneous injection volumes, so inject slowly over 10-15 seconds and hold the needle in place for five seconds after injection to minimize leakage.<\/p>\n","protected":false},"excerpt":{"rendered":"
Where the 5mg Dose Sits in the TRIUMPH Protocol The standard retatrutide dosing ladder runs through four fixed steps: 2 mg, 4 mg, 8 mg, then 12 mg weekly. That’s the structure Eli Lilly defined for the TRIUMPH Phase 3 program, which began enrolling in 2023 across TRIUMPH-1 (NCT05882045 for obesity), TRIUMPH-2 (T2D with overweight), […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-99","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/99","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=99"}],"version-history":[{"count":1,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/99\/revisions"}],"predecessor-version":[{"id":159,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/99\/revisions\/159"}],"wp:attachment":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=99"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=99"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=99"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}